NSEBSE
There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.Open-
High-
Low-
Prev. Close-
Avg. Traded Price-
Volume-
MARKET DEPTH
Total bid0.00
Total ask0.00
HIGH/LOW
LOW/HIGH
₹3,558.202 days ago
₹3,599.902 days ago
SBI Healthcare Opp Fund-Reg(IDCW)
3Y Return+26.1%
NAV₹274.54
UTI Healthcare Fund-Reg(IDCW)
3Y Return+25.6%
NAV₹229.03
Motilal Oswal BSE Healthcare ETF
Tata India Pharma & Healthcare Fund-Reg(G)
Aditya Birla SL Nifty Healthcare ETF
Torrent Pharmaceuticals, the flagship company of the Torrent Group, is one of the leading Pharma companies in India. The company is pioneers in initiating the concept of niche marketing in India and are ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI), women healthcare (WHC), Vitamins Minerals Nutrients (VMN) and Cosmo-Dermatology.The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent Pharma has crossed many geographical boundaries. Through strategic expansions, the company consistently strengthened its global footprint, establishing a robust manufacturing base in India and extending its commercial presence across the world. Its state-of-the-art manufacturing facilities and RD centre, combined with an expanding global network, enable it to bring high-quality medicines to diverse markets.Business area of the companyThe Company is engaged in manufacturing, developing and marketing of generic pharmaceutical formulations. Torrent Pharma is a leading player in the areas of Cardiovascular and Central Nervous Systems, having achieved significant presence in segments of Nephrology, Oncology, Pulmonology, Gynecology and Pediatric treatments.Business segmentsThe company operates in two key business segments - Branded Generics (BGx) and Generics (Gx). Each segment plays a pivotal role in its growth strategy, catering to diverse therapeutic needs across different regions.Branded Generics (BGx):Focuses on manufacturing, marketing and distributing affordable alternatives to off-patented drugs under its own brand names.Generics (Gx):Specialises in manufacturing generic pharmaceutical products after patent exclusivity expires, focusing on markets with regulatory approval for generics.Therapeutic Areas of the companyAnti-DiabeticAnti-MicrobialCardiovascularDermatologicUrologyPainGastro IntestinalGynecologyMiscellaneousOncologyNephrologyNeuro-PsychiatricAwards and recognition1984-85 Received Chemexcil Export Award1984-85 Received Udyog Ratna Award1985-86 Received Chemexcil Export Award1986-87 Received Chemexcil Export Award1986-87 Received IDMA Quality Excellence Award1986-87 Received Export Award from Govt. of Gujarat1987-88 Received Export Award from Govt. of Gujarat1989-90 Received Chemexcil Trishul Award for highest Pharma Exports1989-90 Received IDMA Quality Excellence Award1988-89 Received Chemexcil Export Award1990-91 Received Export Award from Govt. of Gujarat1990-91 Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship1991-92 Received Export Award from Govt. of Gujarat1991-92 Received National Export Award1992-93 Received IDMA Quality Excellence Award1999-00 GCCI Export Appreciation Award1999-00 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility.2000-01 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility2001-02 Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation. 2001-02 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy forits API manufacturing facility2002-03 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities2009-10 Baddi Plant awarded Five Star rating by British Safety Council2012-13 Indrad Plant awarded Sword of Honor for Occupational Health Safety by British Safety Council2014-15 Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 20142017-18 Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine2017-18 Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large CategoryAccreditationApprovals research centreNational GLP Compliance Monitoring Authority, India*National Accreditation Board for Testing Calibration Laboratories (NABL), India*ISO 14001:2004 and OHSAS 18001:2007, ISOQAR Ltd., UK*ISO 50001 : 2011, ISOQAR Ltd. UK*(*Also applicable for Bio-Evaluation Center)Bio-evaluation centre accreditationsThe Drug Controller General (India) (DCGI)ANVISA (BRAZIL)Ministry of Health (UAE)Studies inspected and approvedUSFDAAFFSAPS (ANSM)DKMAAGESANVISAStudies accepted by Regulatory Agencies in:RussiaCIS CountriesAustraliaASEAN countriesSouth AfricaAfrican countriesSouth American countriesMilestones1959: U. N. Mehta started Pharma operations.1971: Trinity Laboratories renamed as Torrent Pharmaceuticals Limited.1980: First manufacturing facility set up at Vatva in Ahmedabad1983: Entry into the international markets. First Export order to USSR received1984: Torrent Laboratories Limited received Chemexcil Export Award.1984: Torrent Laboratories Limited received Udyog Ratna Award.1985: Torrent Laboratories Limited received IMC Golden Jubilee Endowment Award for Export Performance.1985: Torrent Exports Limited received Export Award From Govt. of Gujarat.1985: Torrent Laboratories Limited received IDMA Quality Excellence Award.1985: Torrent Laboratories Limited received Chemexcil Export Award.1986: Torrent Laboratories Limited received Chemexcil Export Award.1986: Torrent Laboratories Limited received IDMA Quality Excellence Award.1986: Torrent Exports Limited received Export Award from Govt. of Gujarat.1987: Torrent Laboratories Limited received Chemexcil Export Award.1987: Torrent Exports Limited received Export Award from Govt. of Gujarat.1989: Second manufacturing plant commissioned at Indrad1989: Torrent Exports Limited received Chemexcil Trishul Award for highest Pharma Exports.1989: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.1988: Torrent Laboratories Limited received Chemexcil Export Award.1990: Torrent Exports Limited received National Export Award.1990: Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship.1992: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.1995: Torrent Gujarat Biotech Limited plant commissioned.1996: U N Mehta bestowed with the title of Corporate Business Man of the Year1998: Torrent Exports renamed as Torrent Ltd. as part of restructuring and consolidation exercise.1998: State-of-the-art RD Centre commissioned.1998: Torrent Pharmaceuticals Limited acquires Pharma related investments and business of Torrent Exports Limited.1999: Restructuring of Torrent Pharmaceuticals Ltd. through formation of three new divisions – Prima, Vista, Psycan.1999: First New Chemical Entity Patented by Torrent Research Center1999: GCCI Export Appreciation Award1999: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility2000: Torrent Research Centre received OECD Standards of Good Lab. Practices Certificate from Dutch Health Ministry.2000: Indrad Plant received ISO 9001:2000 Certificate2001: Torrent Pharma ranked in the top 10 Indian Companies in terms of Return on Capital Employed (ET - BCG Study Feb - 2001).2001: Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation2001: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy for its API manufacturing facility2001: Torrent do Brasil Ltda. set up in Brazil2002: Discovered and patented AGE (Advanced Glycosylation End-products) molecule.2002: Torrent Pharma's Indrad Plant receives ISO 14001:1996 and OHSAS 18001:19992002: Torrent's RD Centre received ISO/IEC 17025:1999 for its facilities by National Accreditation 2002: 2002: Board for Testing and Calibration Laboratories (NABL).2002: Addition of a new marketing division, MIND2002: Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System and Multiparticulate / Matrix Based SR / Modified Release Formulations developed indigenously by Torrent Research Center (2002)2002: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities2002: Brazilian Sanitary Surveillance Agency accredited Torrent's RD Centre with ANVISA, authorizing it to conduct Bioequivalance Studies.2003: Torrent Pharma Inc. set up in USA.2003: GMP Certification received from European Union by Torrent Pharmaceuticals Manufacturing Plant2003: Torrent Pharma Philippines Inc. set up.2004: Torrent Pharma's manufacturing facility at Indrad received MHRA (UK) and TGA (Australia) approvals2004: Restructuring of marketing divisions and addition of new division, Delta.2004: Torrent Australasia Pty Ltd. incorporated in Australia2005: New manufacturing unit at Baddi, Himachal Pradesh, set up to cater to domestic formulations market.2005: Torrent Pharma signed an agreement with Novo Nordisk India to establish a new, dedicated formulation and packaging facility for Insulin, exclusively for Novo Nordisk.2005: Acquired Heumann Pharma GmbH Co Generica KG, a Pfizer group company, in Germany.2005: Two new marketing divisions- AXON and NEURON set up to cater to neuropsychiatry segment.2005: Entered into a research collaboration with AstraZeneca for developing novel anti-hypertensive drug.2005: Torrent Pharma's QC department at Chhatral manufacturing plant accredited with ISO/IEC- 17025 by NABL2006: The API and formulations manufacturing facilities located at Indrad (Gujarat, India) got US FDA approval2006: Torrent Pharma and Pharma Dynamics (Pty) Ltd, South Africa signed a Technical Agreement for supplies of a range of products2007: Indrad Plant certified with ISO 9001: 2000 (Quality Management System), ISO 14001:2004 (Environmental Management System) and OHSAS 180001:1999 (Occupational Health and Safety Management System) by ISOQAR, UKAS accredited body2007: Construction of Sikkim Plant started2008: Baddi Plant received GMP certification from Government of Upper Bavaria, Germany2009: Commissioned dedicated formulation and packaging unit for manufacturing Insulin exclusively for Novo Nordisk2009: Entered into license and supply agreement with AstraZeneca for marketing its products in international market2009: Baddi Plant awarded Five Star rating by British Safety Council2010: Baddi Plant received OHAS Audit 18001:2007certification; facility approved by the regulatory authority of Uganda2010: An advanced facility for Stability Studies set up at Indrad Plant2010: Entered into the therapeutic area of Gynaecology2010: Commenced commercial operations of Laboratories Torrent S.A. de C.V., Mexico2010: Started construction of Dahej manufacturing facility2010: Commissioned a subsidiary in United Kingdom and Romania2010: Torrent Research Center develops Long Acting Injectables technology2010: Foray into oncology segment2011: Sikkim Plant commences operation2011: Indigenous Nasal Drug Delivery system developed by Torrent Research Center2011: Set up Sparsh, a dedicated division to cater to Dermatology Segment2012: Indrad Plant awarded Sword of Honor for Occupational Health Safety by British Safety Council2012: Topical Foams system developed by Torrent Research Center2013: Torrent Pharma enters into a licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab2014: Acquired Elder Pharma's identified Indian Branded Formulation Business in India and Nepal2014: Launched Nephro, a dedicated division to cater to the Nephrology Segment2014: Torrent Pharma's Dahej Plant commences operations2015: Torrent acquires 100% stake of Zyg Pharma2015: Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 20142016: Dahej Plant receives USFDA approval2016: Acquired API manufacturing Unit of Hyderabad based Glochem Industries Limited2017: Acquired Unichem’s Domestic and Nepal business and also its Sikkim manufacturing facility.2017: Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine2017: Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large Category2017: Acquired Women Healthcare brands from Novartis2018: Acquired US based Bio-Pharm, Inc. (BPI) which includes US FDA registered manufacturing facility. This is Torrent's first overseas manufacturing unit.2019: Torrent Glenmark sign licensing agreement for co-marketing of Remogliflozin Etabonate in India2021: Torrent Pharmaceuticals enters into voluntary licensing agreement with Lilly for Baricitinib for Covid-19 in India2021: Cipla, Dr. Reddy’s, Emcure, Sun Pharma and Torrent to collaborate for clinical trial of Molnupiravir for COVID-192022: Torrent Pharma enters into agreement with Dr Reddy's Laboratories2023: Torrent Pharmaceuticals forays into OTC segment with calcium supplement brand2023: Torrent Pharmaceuticals enters into licensing and supply agreement with Zydus Lifesciences2024: Torrent Pharmaceuticals incorporates Wholly Owned Subsidiary in Colombia2024: Torrent Pharmaceuticals enters into patent licensing agreement with Takeda2024: Torrent Pharma enters into agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands2025: Torrent Pharmaceuticals raises Rs 200 crore through Commercial Papers2025: Torrent Pharmaceuticals raises Rs 300 crore through Commercial Papers
